Navigation Links
Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
Date:1/3/2009

EMERYVILLE, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today results describing predictable estrogen regulatory elements that can be used to identify estrogenic drugs that are safer. The data, published in Molecular and Cellular Endocrinology, showed that the new regulatory elements can distinguish the estrogenic pharmacological activity exerted by different compounds and allow for more accurate prediction of specific tissue effect.

"Selective estrogen modulators (SERMs) are an exciting class of drugs that are used to prevent breast cancer and osteoporosis and differ from estrogens in how they regulate gene transcription," said Dr. Dale Leitman, from the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco. "This study identified gene elements that are activated by SERMs but not by estrogens used in hormone therapy. The identification of these elements, coupled with the understanding of the differential regulation in various tissues by each estrogen receptor subtype, provides a new platform for the discovery of safer estrogenic drugs with SERM-like profiles to prevent and treat a variety of clinical conditions associated with menopause."

The study was conducted by investigators at The Center for Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco in collaboration with scientists at Bionovo.

"The discovery of these selective estrogen regulatory elements strengthens our SERM discovery engine," said Isaac Cohen, Bionovo's Chairman and Chief Executive Officer. "The advantage of the new array, of specific regulatory elements, is manifest in the pharmacological and toxicological insights gained. We can now acquire higher predictive value and greater specificity from a complex biological system such as the regulation of the estrogen receptor pathways. I believe this puts Bionovo at the forefront of future SERM products which are far more specific and a more favorable safety profile. This is a breakthrough for all future drugs that regulate the vast diverse effects of conditions affected by nuclear receptors. Bionovo is positioned to explore and exploit these pathways for many serious diseases with its expanded scientific collaborations. We are proud to continue pursuing our innovative approaches to drug discovery and development in these challenging times."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... CORAL GABLES, Fla. , Jan. 23, 2017 ... interdisciplinary network focused on scientific discovery and solutions, ... is creating the Frost Institutes for Science and ... technology, engineering, and mathematics (STEM) to help solve ... University of Miami President Julio Frenk ...
(Date:1/24/2017)... NEW YORK , Jan. 23, 2017  Today, ... to announce they have funded an important study that ... may prevent the onset of Alzheimer,s disease. This groundbreaking ... The Rockefeller University, led by Nobel Laureate Dr. ... cure for Alzheimer,s disease. Fisher Center scientists ...
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... to the fostering of technology and monetization of intellectual ... infringement lawsuits. Anthony Hayes , Chief ... we will continue to communicate with shareholders about the ... our due diligence on other patent assets that fit ...
(Date:1/23/2017)... Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular ... raising $35 million from a syndicate including all Series C ... ... Genetics io┬« system has been completed with the successful CE ... 2016.  This new Series D equity issue will finance the ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
(Date:12/22/2016)... Calif. , Dec. 20, 2016  As part of ... 23andMe, the leading personal genetics company, recently released its latest ... . The book focuses on the topics of inheritance ... Generation Science Standards (NGSS) taught in elementary school classrooms in ... in a series by illustrator Ariana Killoran , whose ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
Breaking Biology News(10 mins):